Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Jan 9;145(2):244-247.
doi: 10.1182/blood.2024025707.

Long-term follow-up of the STOPAGO study

Adrien Cottu  1 , Stéphanie Guillet  1 , Jean-François Viallard  2 , Etienne Rivière  2 , Stéphane Cheze  3 , Delphine Gobert  4 , Antoine Neel  5 , Julie Graveleau  5 , Jean-Pierre Marolleau  6 , François Lefrere  7 , Guillaume Moulis  8   9 , Jean-Christophe Lega  10 , Aline Moignet-Autrel  11 , Ailsa Robbins  12 , Etienne Crickx  1   13   14 , Emmanuelle Boutin  15   16 , Nicolas Noel  17 , Marion Malphettes  18 , Lionel Galicier  18 , Sylvain Audia  19 , Bernard Bonnotte  19 , Olivier Lambotte  17 , Olivier Fain  4 , Mathieu Gerfaud-Valentin  20 , Louis Terriou  21 , Nihal Martis  22 , Anne-Sophie Morin  23 , Antoinette Perlat  11 , Thomas Le Gallou  11 , Frédérique Roy-Peaud  24 , Matthieu Puyade  25 , Thibault Comont  26 , Nicolas Limal  1 , Laetitia Languille  1 , Marc Michel  1 , Bertrand Godeau  1 , Matthieu Mahevas  1   13   27
Affiliations
Clinical Trial

Long-term follow-up of the STOPAGO study

Adrien Cottu et al. Blood. .

Abstract

In an open prospective, multicenter study enrolling 48 selected patients with chronic immune thrombocytopenia who achieved complete response for 1 year on thrombopoietin receptor agonists, half of the patients maintained a sustained response off treatment 4 years after treatment discontinuation.

Trial registration: ClinicalTrials.gov NCT03119974.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: M. Mahevas received funds for research from GlaxoSmithKline and lecture fees from Amgen and Novartis. B.G. served as an expert for Amgen, Novartis, Grifols, and Sobi. M. Michel received honoraria (advisory boards and speaker fees) from Novartis, Amgen, Union Chimique Belge (UCB), Argenx, Alexion, and Sanofi. E.C. received honoraria (advisory boards and speaker fees) from Novartis, UCB, and Sanofi. The remaining authors declare no competing financial interests.

References

Publication types

Associated data

LinkOut - more resources